Bangkok Dusit Medical Services Public Company Limited
Bangkok Dusit Medical Services Public Company Limited (BDUUY) Financial Performance & Income Statement Overview
Review Bangkok Dusit Medical Services Public Company Limited (BDUUY) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Bangkok Dusit Medical Services Public Company Limited (BDUUY) Income Statement & Financial Overview
Explore comprehensive income reports for Bangkok Dusit Medical Services Public Company Limited BDUUY, broken down by year and quarter.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $28.08B | $27.40B | $28.15B | $25.70B |
| Cost of Revenue | $17.69B | $17.04B | $17.63B | $16.66B |
| Gross Profit | $10.40B | $10.37B | $10.52B | $9.04B |
| Gross Profit Ratio | $0.37 | $0.38 | $0.37 | $0.35 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $5.15B | $5.48B | $5.31B | $5.15B |
| Operating Expenses | $4.77B | $5.04B | $4.91B | $4.77B |
| Total Costs & Expenses | $22.83B | $22.50B | $22.93B | $21.81B |
| Interest Income | $31.40M | $39.02M | $40.17M | $47.46M |
| Interest Expense | $97.12M | $107.87M | $102.42M | $110.56M |
| Depreciation & Amortization | $1.62B | $1.60B | $1.55B | $1.50B |
| EBITDA | $7.30B | $6.99B | $7.22B | $5.82B |
| EBITDA Ratio | $0.26 | $0.26 | $0.26 | $0.23 |
| Operating Income | $5.62B | $5.32B | $5.61B | $4.27B |
| Operating Income Ratio | $0.20 | $0.19 | $0.20 | $0.17 |
| Other Income/Expenses (Net) | -$47.13M | -$43.68M | -$38.33M | -$49.05M |
| Income Before Tax | $5.58B | $5.28B | $5.57B | $4.22B |
| Income Before Tax Ratio | $0.20 | $0.19 | $0.20 | $0.16 |
| Income Tax Expense | $1.08B | $840.60M | $1.15B | $756.08M |
| Net Income | $4.35B | $4.33B | $4.25B | $3.33B |
| Net Income Ratio | $0.15 | $0.16 | $0.15 | $0.13 |
| EPS | $0.27 | $0.27 | $0.27 | $0.21 |
| Diluted EPS | $0.27 | $0.27 | $0.27 | $0.21 |
| Weighted Avg Shares Outstanding | $15.89B | $15.89B | $15.89B | $15.89B |
| Weighted Avg Shares Outstanding (Diluted) | $15.89B | $15.89B | $15.89B | $15.89B |
Financial performance has remained strong, with revenue growing from $25.70B in Q2 2024 to $28.08B in Q1 2025. Gross profit continued to perform well, with margins at 37% in the latest quarter. Operating income reached $5.62B in Q1 2025, holding a steady 20% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $7.30B. Net income rose to $4.35B, keeping EPS at $0.27. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan